Main Article Content
Malignancy, COVID-19, Clinical Characteristic
Introduction: Recently, Covid 19 as a fatal virus has been known as the cause of the pandemic. Different number of the mortality rate in various societies have been reported. However, it seems the underlying comorbidities increase the risk of mortality and the severity of presentation. In this study we evaluated the pattern of presentation of COVID-19 among cancerous patients in terms of severity.
Method: between 20th February to 22nd April of 2020, among 214 hospitalized patients because of COVID-19. 41 patients revealed the cancer as a synchronous comorbidity. These patients based on the severity of COVID-19 infection presentation were divided to mild and severe groups. Then, the demographic characteristics, manifestation and laboratory data between these groups were compared.
Result: about 19 (46.34%) of 41 cases were categorized as severe forms of COVID-19 with malignancy. The mean age of severe groups was significantly higher (P=0.00). Dyspnea (48.78%), cough (46.34%) and myalgia (24.39%) were the most common clinical features among cancerous patients with COVID-19. diarrhea and nearly cough caused significant effects on severe form of presentation of COVID-19 infection (P=0.05, P=0.06, respectively). Hematological cancers were the most frequent types of cancer among these patients (46.34%). White Blood Cell counts were significantly lower in severe groups (P=0.03, P=.0.06, respectively). C-reactive protein is another item that nearly significantly was higher in severe groups of cancerous patients (P=0.06).
Conclusion: The elderly age, the positive chemotherapy history, diarrhea, cough, declined WBC, PLT and elevated CRP correlated with a severe form of this infection in malignant cases.
2. Torkian P, Ramezani N, Kiani P, Bax MR, Akhlaghpoor S. Common CT Findings of Novel Coronavirus Disease 2019 (COVID-19): A Case Series. Cureus 2020; 12: e7434-e.
3. Centers for Disease Control and Prevention (CDC). Human Coronavirus Types . Available: https://www.cdc.gov/coronavirus/types.html [Accessed june,16 2020].
4. Moazzami B, Razavi-Khorasani N, Dooghaie Moghadam A, Farokhi E, Rezaei N. COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being. J Clin Virol 2020; 126: 104345.
5. Baradaran A, Ebrahimzadeh MH, Baradaran A, Kachooei A. Prevalence of Comorbidities in COVID-19 Patients: A Systematic Review and Meta-Analysis. Arch Bone Jt Surg 2020; 8: 247-255.
6. Onder G, Rezza G, Brusaferro S . Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323: 1775-1776.
7. Zhang L, Zhu F, Xie L, Wang C , Wang J , Chen R , Jia P , Guan HQ , Peng L , Chen Y , Peng P , Zhang P , Chu Q , Shen Q , Wang Y , Xu SY , Zhao JP , M. Zhou M. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020; 31:894-901.
8. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J . Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337.
9. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med 2020; 8 : e35.
10. Sahu KK, Jindal V, Siddiqui AD. Managing COVID-19 in Patients With Cancer: A Double Blow for Oncologists. JCO Oncol Pract 2020; 16: 223-5.
11. Spicer J, Chamberlain C, Papa S . Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol 2020; 17: 329-331.
12. van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D , Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F , Garralda E, Piris-Giménez A, Baumann M, Apolone G , Charles Soria J, Tabernero J, Caldas C, Voest E. Caring for patients with cancer in the COVID-19 era. Nature Medicine 2020; 26: 665-671.
13. Gosain R, Abdou Y, Singh A, Rana N , Puzanov I , Ernstoff M . COVID-19 and Cancer: a Comprehensive Review. Curr Oncol Rep 2020; 22: 53.
14. Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study. J infect2020; 9:45.
15. Kong Q, Xiang Z, Wu Y, Gu Y , Guo J , Geng F. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection. Molecular cancer 2020; 19: 80.
16. Extance A . Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease? Bmj 2020; 368: 1174.
17. Raskin J, Lebeer M, De Bondt C, Wener R, Janssens A, P. van Meerbeeck J. Cancer in the time of COVID-19: expert opinion on how to adapt current practice. Eur Respir J 2020; 55.
18. Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, Xuan-Yong Liu XY, Liu HM , Guo Z , Ren H, Wang Q . Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 2020; 1-9.